Patents Assigned to Merck Sharp & Dohme LLC
-
Patent number: 12291538Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, Cy, Cz, R1, R2, R3, R4, R2a, Ry, Rz, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: GrantFiled: May 3, 2023Date of Patent: May 6, 2025Assignee: Merck Sharp & Dohme LLCInventors: Indu Bharathan, Symon Gathiaka, Yongxin Han, Xiaoshen Ma, Ryan D. Otte, David L. Sloman, Thomas H. Graham, Timothy Henderson, Elisabeth Hennessy, Anandan Palani
-
Publication number: 20250136910Abstract: In some embodiments, devices for use as blood-brain barrier models are disclosed. The devices may include either a hydrogel component that surrounds a channel formed between a first opening and a second opening of the hydrogel component, or a hydrogel component that forms a groove. The devices may further include pericytes disposed in the channel or the groove, and endothelial cells may be disposed in the channel or the groove. The hydrogel component may include astrocytes (e.g., printed into the hydrogel component via projection stereolithography). Also disclosed are various methods of making and using these devices.Type: ApplicationFiled: October 16, 2024Publication date: May 1, 2025Applicants: Merck Sharp & Dohme LLC, William Marsh Rice UniversityInventors: Nicole L. Buist, Martha J. Fowler, Yufang He, Anna Kristen Mai, Adam T. Procopio, Madison K. Royse, Omid Veiseh, Jun Xu
-
Publication number: 20250127879Abstract: Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.Type: ApplicationFiled: June 7, 2024Publication date: April 24, 2025Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, MEMORIAL SLOAN KETTERING CANCER CENTER, MERCK SHARP & DOHME LLCInventors: Peter PALESE, Adolfo GARCIA-SASTRE, Dmitriy ZAMARIN, Svetlana SADEKOVA, Rachel Allison ALTURA, Uyen PHAN, Brian B. HAINES, Jedd D. WOLCHOK
-
Patent number: 12281109Abstract: The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing cancer, inflammation, neurodegeneration disease and/or diabetes in a subject.Type: GrantFiled: March 30, 2020Date of Patent: April 22, 2025Assignee: Merck Sharp & Dohme LLCInventors: Jian Liu, Younong Yu, Joseph A. Kozlowski, Deyou Sha, Wensheng Yu, Joseph M. Kelly, Scott E. Wolkenberg
-
Patent number: 12280107Abstract: The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.Type: GrantFiled: February 15, 2023Date of Patent: April 22, 2025Assignee: Merck Sharp & Dohme LLCInventors: William J. Smith, Cecilia Giovarelli, Denise K. Nawrocki
-
Patent number: 12275729Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: October 29, 2018Date of Patent: April 15, 2025Assignee: Merck Sharp & Dohme LLCInventors: Yongqi Deng, Abdelghani Achab, David Jonathan Bennett, Indu Bharathan, Xavier Fradera, Craig Gibeau, Yongxin Han, Derun Li, Kun Liu, Qinglin Pu, Sulagna Sanyal, David Sloman, Wensheng Yu, Hongjun Zhang
-
Patent number: 12275800Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: GrantFiled: April 18, 2023Date of Patent: April 15, 2025Assignees: Merck Sharp & Dohme LLC, Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
-
Patent number: 12263171Abstract: In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.Type: GrantFiled: November 26, 2019Date of Patent: April 1, 2025Assignee: Merck Sharp & Dohme LLCInventors: Yonglian Zhang, Amjad Ali, Jared Cumming, Duane DeMong, Qiaolin Deng, Thomas H. Graham, Elisabeth Hennessy, Matthew A. Larsen, Kun Liu, Ping Liu, Umar Faruk Mansoor, Jianping Pan, Christopher W. Plummer, Aaron Sather, Uma Swaminathan, Huijun Wang
-
Patent number: 12264139Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.Type: GrantFiled: June 10, 2021Date of Patent: April 1, 2025Assignee: Merck Sharp & Dohme LLCInventors: Yongxin Han, Jongwon Lim, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer
-
Patent number: 12264134Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: November 25, 2019Date of Patent: April 1, 2025Assignee: Merck Sharp & Dohme LLCInventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
-
Publication number: 20250099478Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: January 23, 2023Publication date: March 27, 2025Applicant: Merck Sharp & Dohme LLCInventors: Anthony K. Ogawa, Christopher J. Sinz, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Rohan Rajiv Merchant, Natalija Cernaka, Phillip Patrick Sharp, Jovan Alexander Lopez, Dong Xiao, Haiqun Tang, Maoqun Tian, Mihir B. Mandal, Jiafang He
-
Publication number: 20250101097Abstract: This disclosure relates to methods for treating cancer in a subject identified as having acute myeloid leukemia (AML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).Type: ApplicationFiled: July 25, 2022Publication date: March 27, 2025Applicant: Merck Sharp & Dohme LLCInventors: Cai Wu, Daping Zhang, Jie Zhang-Hoover
-
Patent number: 12258329Abstract: The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: GrantFiled: December 13, 2019Date of Patent: March 25, 2025Assignee: Merck Sharp & Dohme LLCInventors: Antonella Converso, Cheng Wang
-
Publication number: 20250084064Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: November 26, 2024Publication date: March 13, 2025Applicant: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L.G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Publication number: 20250084123Abstract: The present invention provides a method for multiproduct resin reuse (MRR) utilizing ionic exchange chromatography columns. The methods of the invention outline the cleaning steps necessary for reuse as well as the analytical processes used in determining product carryover from production of one product to the next. The invention outlines a successful MRR strategy that can be utilized not just in lab-scale studies, but in a GMP manufacturing setting.Type: ApplicationFiled: August 9, 2024Publication date: March 13, 2025Applicant: Merck Sharp & Dohme LLCInventors: Collette M. Cutler, Hong Li, Ren Liu, Jeffrey T. McPhee, Douglas Dennis Richardson, II, Patricia A. Rose, Patricia Rowicki
-
Patent number: 12246008Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.Type: GrantFiled: December 2, 2019Date of Patent: March 11, 2025Assignee: Merck Sharp & Dohme LLCInventors: Christopher J. Bungard, Helen Y. Chen, Jason M. Cox, Liangqin Guo, Michael J. Kelly, III, Ronald M. Kim, Mark E. Layton, Hong Liu, Jian Liu, Mehul F. Patel, James J. Perkins, Deping Wang, Walter Won, Younong Yu, Ting Zhang
-
Patent number: 12247031Abstract: The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: December 6, 2019Date of Patent: March 11, 2025Assignee: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhuyan Guo, Zhong Lai, Dongfang Meng
-
Publication number: 20250073254Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.Type: ApplicationFiled: November 13, 2024Publication date: March 6, 2025Applicant: Merck Sharp & Dohme LLCInventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
-
Publication number: 20250074985Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.Type: ApplicationFiled: September 11, 2024Publication date: March 6, 2025Applicant: Merck Sharp & Dohme LLCInventors: Soumendu Bhattacharya, Chakravarthy Nachu Narasimhan, Manoj K. Sharma, Xiaoyu Yang, Arnab De, Rubi Burlage, Jason K. Cheung
-
Publication number: 20250074983Abstract: The invention relates to methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody, or antigen binding fragment thereof, (e.g. pembrolizumab), in specific amounts to the patient. In some embodiments, the administration occurs about every three weeks. In some embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 280 mg to about 450 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.Type: ApplicationFiled: April 4, 2022Publication date: March 6, 2025Applicant: MERCK SHARP & DOHME LLCInventors: Mallika LALA, Carolina DE MIRANDA SILVA, Ferdous GHEYAS, Yogita KRISHNAMACHARI, Elliot Keith CHARTASH, Lokesh JAIN, Venkata Naga Ratna Pavan Kumar VADDADY